Floor J. Backes, MD, discusses the immunotherapeutic options available for treatment of patients with ovarian cancer.
Floor J. Backes, MD
Advertisement
Articles by Floor J. Backes, MD
Floor J. Backes, MD, discusses the side effects associated with the combination lenvatinib plus paclitaxel in patients with recurrent endometrial and platinum-resistant epithelial ovarian cancer.
Floor J. Backes, MD, discusses the results from a phase I trial investigating the combination of lenvatinib (Lenvima) and paclitaxel in patients with recurrent ovarian, fallopian tube, or peritoneal cancers.
Advertisement
Latest Updated Articles
Combination Regimens May Improve Responses in Ovarian CancerPublished: March 3rd 2020 | Updated:
Investigating Toxicities With Lenvatinib Plus Paclitaxel in Ovarian and Endometrial CancersPublished: May 17th 2019 | Updated:
Evaluating the Benefits of Lenvatinib and Paclitaxel in Recurrent Gynecologic CancersPublished: March 18th 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5
